A phase II international multicentre randomised open label study of oral steroid sulphatase inhibitor BN83495 versus megestrol acetate (MA) in women with advanced or recurrent endometrial cancer

• Conditions: Advanced or recurrent endometrial cancer; MedDRA version: 9.1Level: LLTClassification code 10014733Term: Endometrial cancer

• Registration Number: EUCTR2009-010613-68-HU
• Lead Sponsor: Ipsen Pharma

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-10-12
• Last Update Posted: 22 July 2013

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

1. Provision of written informed consent prior to any study related procedures.
2. Post-menopausal or ovariectomised female patients over the age of 18 years with advanced or recurrent endometrial cancer.
3. Histologically confirmed diagnosis of endometrial carcinoma.
4. Not eligible for surgery or radiotherapy.
5. Document ER and/or PR positivity in the primary tumour. ER positive is defined by at least 10% positive cells where the information is available.
6. No other history of malignant disease except treated basal cell or in situ cervical carcinoma.
7. Eastern Cooperative Oncology Group (ECOG) performance status =2.
8. At least one measurable disease site (RECIST criteria version 1.0)
- minimum indicator lesion size: 20mm (conventional techniques) or 10mm (spiral CT scan)
- target lesions not situated in irradiated area
9. Life expectancy =6 months.
10. Adequate organ function as defined by the following criteria:
- Haemogolobin =10g/dL
- Absolute neutrophil count (ANC) =1500/µL
- Platelets =100,000/µl
11. Patients must have recovered from surgery, radiotherapy and toxicities of adjuvant chemotherapy treatment if applicable.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Use of any investigational agent in the 4 weeks prior to enrolment in this study
2. Prior systemic treatment for endometrial cancer (including hormonal treatment, chemotherapy, antiangiogenic or targeted therapies) with the exception of chemotherapy in the adjuvant setting having been completed at least 1 year prior to randomisation.
3. Known central nervous system (CNS) metastases
4. Ongoing cardiac dysrhythmias of NCI CTC adverse event (AE) grade =2, atrial fibrillation of any grade, QTcF interval >460 msec
5. Patients with contraindications to MA including hypersensitivity to one of the components of the drug product, any significant arterial or venous thromboembolic event and/or uncontrolled hypertension
6. Concomitant use of systemic carbonic anhydrase II inhibitors (e.g. acetazolamide, dichlorphenamide, methazolamide)
7. History of hypersensitivity to BN83495 or drugs with a similar chemical structure.
8. Likely to require treatment during the study with drugs that are not permitted by the study protocol (see Section 9.6).
9. Abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the patient's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified